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We read with great interest the article reporting on the
efficacy and safety of acupuncture and nimodipine ther-
apy for the treatment of mild cognitive impairment after
cerebral infarction [1]. We would like to highlight that
the article by Wang and colleagues reports outcomes
that differ from those initially described [2]. The article
reference the pre-specified primary outcomes (efficacy) and
only one (Montreal Cognitive Assessment, “MoCA”) of the
six pre-specified secondary outcomes. The CONSORT
guidelines on the best practice in a trial reporting [3] are
implemented to reduce the risk of selective outcome
reporting and require that all pre-specified primary and
secondary outcomes be reported.
Additionally, we would like to highlight the inappropri-
ate use of statistical tests performed in this manuscript.
The analysis performed does not make justice to the con-
siderable effort realized by the authors in this manuscript.
Although reanalyzed, based in the supplementary data
provided, there were no major changes to the results pre-
sented by them; but, such an inappropriate use of statistics
should never pass the peer review process and BMC Com-
plementary and Alternative Medicine should notice that.
The authors indicate that “For intra-group comparison
of MoCA score improvement at the end of 3-month therapy
versus that at the follow-up, Kruskal-Wallis rank sum
test was used for the acupuncture alone group; independent
sample t-test was used for the nimodipine alone and
nimodipine + acupuncture groups. Kruskal-Wallis rank sum
test was used for comparison of percentage improvement of
MoCA score at the end of 3-month therapy versus that at
the follow-up in each group”. The appropriate statis-
tical test for analyzing two groups in a longitudinal
study is not the Kruskal–Wallis test; if you want a
non-parametric test, please use the Wilcoxon signed-
rank test because under the same treatment, MoCA
measurements are dependent between baseline, at the end
of treatment and at the follow-up. The Kruskal-Wallis
rank sum test is intended for unrelated samples (for ex-
ample, inter-group comparisons and always more than
two groups). The use of an “independent sample t-test” is
also inappropriate for intra-group comparisons because
measurements are dependent, as patients are always the
same at baseline, at the end of treatment and at the
follow-up. Additionally, the nimodipine alone data is not
normally distributed (P < 0.001 in the Kolmogorov-
Smirnov test at baseline, at the end of 3-month treatment,
and at the follow-up); therefore, a parametric test such as
the t-test should not be used. Similarly, in the nimodipine
+ acupuncture group, neither baseline (P = 0.026 in the
Kolmogorov-Smirnov test) nor the follow-up (P = 0.030 in
the Kolmogorov-Smirnov test) data are normally distrib-
uted; therefore, a parametric test cannot be used. Alterna-
tively, authors should use the Wilcoxon signed-rank test
for the two intra-group comparisons.
Inter-group comparisons, when performed between
two groups, are also incorrectly used; an appropriate test
would be the Mann–Whitney U test or a similar test,
not the Kruskal-Wallis rank sum test, which is intended
for use when there are more than two groups.
Using the appropriate statistical test, the mean MoCA
score increased significantly (P < 0.0001) among all the
comparisons at the end of the 3-month treatment com-
pared to baseline values, and a further increase that
remained significantly higher at the 3-month follow-up was
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observed, as the authors indicated. Additionally, the mean
percentage of MoCA improvement at the follow-up was
higher than that at the end of the 3-month treatment under
all treatments (P = 0.022 for nimodipine alone, P < 0.001 for
acupuncture, and P < 0.001 for nimodipine + acupuncture).
These results suggest that all 3 therapies may improve
cognitive function under the studied circumstances.
However, MoCA scores at the follow-up did not differ
significantly between the acupuncture alone group
(26.1 ± 3.6) compared to the nimodipine alone group
(24.2 ± 4.6) (P = 0.055), and there were no statistically
significant differences between the nimodipine + acupunc-
ture MoCA score (26.0 ± 2.8) and that of the nimodipine
alone group (P = 0.086). Similar results were observed at
the end of the treatment period; therefore, no significant
differences were found in the inter-group comparisons
with respect to the MoCA score.
Although reanalyzed data using the appropriate statis-
tical tests did confirm some of the data presented by the
authors, it is questionable that such results indicate that
the combinatory therapy of nimodipine and acupuncture
shows superior efficacy on post-cerebral infarction MCI
to nimodipine monotherapy and acupuncture monother-
apy. Clinical relevance is not automatically evidentiated
if there is statistical significance. The cause(s) may be
that the sample is too small and/or the dispersion is too
high. Thus, a decision for clinical significance under the
study circumstances on the basis of the P-value alone
may be simplistic.
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